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Open access under Hormone determinations are of central importance to the practice
of Clinical Endocrinology, and ensuring their correct use and per-
formance is a multidisciplinary responsibility involving clinicians,
laboratory staff, manufacturers of diagnostic systems and health-
care regulatory agencies. All these professional groups have,
therefore, an interest in external quality assessment (EQA) as an
audit tool that can identify areas where use of tests in routine
practice requires improvement to reduce risks to patients.
This chapter reviews the principles of EQA, and outlines its
strengths and limitations, illustrated with example data from the
UK National External Quality Assessment Service (UK NEQAS). The
immunological nature of many hormone assays, often further
complicated by heterogeneity of analyte structure and lack of
suitable calibrators, presents special problems for the designers of
EQA schemes in ensuring that specimens are appropriate and that
target values are accurate.
Laboratory users of EQA should have sufﬁcient knowledge of the
characteristics of the EQA schemes in which they participate to
make informed interpretation of their data. The trend since the
1980s for in-house assays designed in individual laboratories to be
superseded by automated assays provided by a small number of
diagnostics manufacturers places a special responsibility on
manufacturers to ensure reliable assay design and calibration. In
collaboration with other parties EQA can help identify priorities for
improved assay design and calibration.
Although traditionally the focus of EQA has been on assessing the
analytical phase it can also make some assessment of other
important aspects of performance, e.g. the consistency of reference
ranges and how results are interpreted.2.
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and as an educational resource, thereby helping to ensure and
improve the quality of laboratory services that support patient
care.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Laboratory test results contribute signiﬁcantly to diagnostic decision-making, particularly in
endocrinology, where their appropriate use is of key importance to delivering the best clinical
outcomes for patients and enabling efﬁcient use of health care resources. In practice, this means
that the correct test(s) should be selected, the correct specimen taken from the correct patient at
the correct time, the analysis performed using an accurate and reliable method, and the results
interpreted appropriately. Together, these steps are a shared responsibility requiring multidisci-
plinary input (Fig. 1). Clearly the infrastructure and management of hospitals and health centres
will vary in different countries. Regional and national policies, including arrangements for labo-
ratory accreditation and clinical governance, shape and inﬂuence the laboratory service provided
for all tests, including endocrine analytes. These broad strategic issues are critically important but
are beyond the scope of this chapter, which will focus on how external quality assessment can
serve as an audit tool to ensure and improve the quality of laboratory testing in clinical
endocrinology.
From its inception [1], EQA has focussed on the technical aspects of the analysis, but with changes in
laboratory practice and increasing awareness that errors can occur in all stages of laboratory testing –
from pre-analytical, through analytical to post analytical (Table 1) – the focus of EQA and related audit
has broadened to address wider aspects of investigative testing. EQA of the analytical phase remains
the core activity of EQA, however, although even here the focus of interest has changed over time, as in-
house and manual immunoassays have been superseded by automated assays using reagent kits. The
end user has limited control over these, and the onus of responsibility for analytical quality has shifted
substantially towards the providers of automated analysers. All these changes have implications for
providers of EQA schemes, participating laboratories, accreditation agencies and clinicians who use
laboratory services.
In this chapter the design and operation of EQA of the analytical stage is described, and how EQA
and other audit surveys can be extended to assess the pre-analytical and post-analytical stageso the effective use of endocrine tests in clinical care.
Table 1
Some causes of error in laboratory investigations in clinical endocrinology.
Pre-analytical Specimen collected at the wrong time (day, time of menstrual cycle etc)
Incorrect type of specimen (serum, plasma)
Unstable specimen delayed in reaching laboratory
Specimen mis-labelling in laboratory reception
Analytical Assay bias (incorrect calibration)
Assay imprecision (sampling errors, unstable assay system)
Background interference
Interfering substances in specimen (endogenous antibodies, drugs, preservatives in EQA specimens)
High-dose hook effects
Post-analytical Incorrect linkage of results to specimen
Use of incorrect concentration units
Use of incorrect reference ranges
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Assessment Service (UK NEQAS) Endocrinology schemes with data from other audits where
appropriate.
Requirements for EQA schemes in endocrinology
The core features required of an EQA scheme for hormone assays are summarised in Table 2. It will
be clear at the outset that EQA differs from IQC in several crucial respects. IQC is primarily a process that
controls and ensures the consistency of a laboratory results before they are released, while EQA pro-
vides retrospective assessment of the comparability of a laboratory’s results with results for the same
specimen(s) reported by other laboratories. EQA specimens cannot be used for IQC and both pro-
cedures are an integral part of good laboratory practice.
Specimen distribution frequency and reporting requirements
In many countries participation in relevant EQA schemes is an essential requirement for laboratory
accreditation and the EQA scheme itself must be accredited. However details of scheme provision are
not speciﬁed and vary from minimal [e.g. two distributions (or surveys) of two specimens per year] to
the much more intense (e.g. twelve distributions of ﬁve specimens per year). What constitutes
appropriate EQA for an analyte is determined by several factors, including the structural complexity of
the analyte, the maturity of the assay technology, and the purpose of the scheme. For example, rela-
tively simple schemes with less frequent specimen distribution may be suitable for structurally ho-
mogeneous analytes where assay technology is well-developed and reliable, and all that is required is
demonstration that results are sufﬁciently close to the target values to fulﬁl regulatory requirements.
However, more intensive monitoring may be valuable for molecularly heterogeneous analytes which
are variably recognised in different immunoassays. More intensive and critical probing of reasons for
method-related differences in results is possible using carefully constituted specimens. This can help to
highlight the potential effect of such differences on patient care (e.g. decision limits for treatment) both
to laboratory users and to manufacturers of the methods.
Most UK NEQAS endocrinology schemes distribute 3 to 5 specimens monthly. As well as
enabling more in-depth probing of clinically relevant issues (e.g. interference from macroprolactin
in prolactin methods), this frequency provides a sounder statistical basis for assessing cumulative
performance.
Accurate documentation of reporting units and methods used by participants is demanding but
essential if valid conclusions are to be drawn from the data. Although for some analytes there are
national and/or international initiatives to encourage reporting of endocrine results in the same units
of the same International Standard (IS) [e.g. mg/L of IS 98/574 for growth hormone (GH) [2]], for others
different units are still used [e.g. ng/L and pmol/L for parathyroid hormone (PTH) [3]] while for others
there is no established IS [e.g. adrenocorticotrophin hormone (ACTH) [4]]. Analysing results in terms of
the same units of the same reference standard is a pre-requisite for meaningful interpretation of EQA
Table 2
Key requirements of EQA for hormone assays. [See text for detailed discussion].
EQA scheme feature Requirements
Specimen distribution frequency and
reporting requirements
Number of distributions per annum and specimens per distribution
sufﬁcient to give adequate statistical estimates of laboratory
performance, ﬁt for the purpose of the scheme. Complex analytes
(e.g. where there are speciﬁcity issues) may require more
intensive monitoring
Accurate documentation of methods
Results expressed in the same units and in terms of
the appropriate International Standard where relevant with
web-based data entry preferable and penalties for
non-returns or late returns
EQA specimens handled as if they were patient specimens
Specimen material distributed Specimen matrix identical to or resembling as closely as
possible patient specimens (i.e. commutable specimens)
Analyte concentrations appropriate to the clinical use of the test
and especially those close to decision levels of the test
Free from avoidable infectious hazards (e.g. negative for
hepatitis B, hepatitis C and HIV antigens)
Stability and homogeneity conﬁrmed (before and after reconstitution
if lyophilised) and stable under conditions of specimen distribution
Deﬁnition of target values Evidence that the targets [reference method values for
accuracy-based schemes or consensus values determined
using appropriate statistics] are accurate and stable on
repeat distribution of the same pool.
Assessment of overall performance Based on rolling time window, with sufﬁcient specimens to
give statistically reliable estimates of bias from target and
scatter of bias
Assessment of trends in performance over time
Assessment of individual
method performance
Provision of estimates of bias and precision of individual
methods, requiring sufﬁcient number of users of each
method and taking account of possible different
reagent//calibrator formulations within a method
Assessment of analytical speciﬁcity and sensitivity
Assessment of method robustness to
clinically relevant interference
Occasional exercises to test suitability of methods for
routine use, e.g. interference from heterophilic and other
antibody complexes, medication, high-dose hook effects
Assessment of individual laboratory
performance
Provision of estimates of bias and precision of individual
laboratories in a clear and concise way
Personalised computerised EQA reports returned rapidly
so as to permit early remedial action if needed
Identifying, conﬁrming and recording errors made by participants
Scoring of performance and external review
Communication with participating
laboratories
Participants and manufacturers offered easy routes of
communication to discuss problems.
Preferable for EQA staff to have practical experience in
diagnostic laboratory setting
Audit of wider aspects of analytical
performance and educational activities
Appropriateness of test requesting
Patient preparation and time of sampling
Audit of pre-analytical practice (e.g. advice about
specimen stability, transport and storage)
Surveys of post-analytical practice (e.g. interpretation,
reference intervals)
Provision of additional information (e.g. method-related
and network reports, literature surveys)
Active dialogue with participants, manufacturers and
regulatory agencies both routinely and at participant meetings
Table based on Tables 2 and 9 in Reference [33].
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scheme units using appropriate conversion factors. Similarly, where there is more than one formula-
tion of the same method in the ﬁeld (e.g. in the interim period after a re-standardised method is
available but before all users have started using the new version) and when results differ, a temporary
method code should be assigned to the “old” method so that results using the two versions can be
differentiated and any implications for clinical interpretation (e.g. reference intervals) clearly
demonstrated.
It is of course essential that participants treat their EQA specimens under conditions identical to
those applied to clinical specimens. Preferential treatment (e.g. analysing in triplicate when clinical
specimens are analysed in singleton) may give an optimistic view of performance. Such mis-use is
probably less likely in schemes where the educational role of the schemes is emphasised and the ethos
promoted is a collaborative one in which EQA is viewed primarily as one important part of a collective
effort among professionals, aimed at improving services, rather than as having an external policing
remit [5]. In this respect it can be helpful if EQA providers are themselves practicing laboratory pro-
fessionals who are acquainted with the realities of routine service provision.
Specimen material distributed
A fundamental requirement is that the immunoreactivity of an analyte in EQA specimens closely
resembles that observed in patient specimens, i.e. that the matrix of the EQA specimens is similar to
that of the clinical specimens being measured and that the EQA specimens are commutable. A
commutable EQA specimen demonstrates the same numeric relationship between different mea-
surement procedures as that expected for patient specimens [6]. As is also the case for IQC, EQA
specimens prepared in a buffer or other artiﬁcial diluent may provide an over-optimistic assessment of
performance. Generally EQA specimens prepared from normal human serum or plasma with minimal
processing would be expected to be commutable but ideally this should be conﬁrmed experimentally.
In the UK NEQAS for Peptide Hormones, liquid sera are ﬁltered down to 0.2 microns and a preservative
(0.5% v/v Kathon) is added. Use of sodium azide was discontinued some years ago after it was
established that it affected luteinising hormone (LH) and human chorionic gonadotrophin (hCG) im-
munoassays provided by onemanufacturer although it had no effect on any others tested. It is therefore
important to conﬁrm that any additives do not affect immunoassays being assessed. Safety consider-
ationsmust also bemet andmost EQA providers ensure that specimens for endocrine tests are negative
for hepatitis B and C antigens and HIV antibodies.
Analyte concentrations should be appropriate to the clinical applications of the analyte, with
particular focus on concentrations near clinical decision points, e.g. 1.0 mg/L of growth hormone for the
diagnosis of acromegaly [7]. Acquiring patient material of appropriate concentration in sufﬁcient
volumes for preparation of specimens can be challenging for some analytes [e.g. ACTH, prolactin] and it
may be necessary to add puriﬁed analyte to a base pool of normal serum or plasma. The risk of non-
commutability is likely to be higher for such specimens, especially for heterogeneous analytes such
as the peptide hormones.
Analyte stability in EQA specimens during transit to participating laboratories must also be
demonstrated, both within the country of origin and further aﬁeld, since many schemes distribute
specimens worldwide. This can be difﬁcult, since different specimens for the same analyte may not
be equally stable and an analyte which is stable when measured in some immunoassays may not be
stable in others. Lyophilised rather than liquid specimens are essential for some unstable analytes
(e.g. ACTH, calcitonin, gastrin, insulin and PTH) while for others (e.g. hCG) they can reduce errors
due to instability. However lyophilisation may introduce other errors, e.g. loss due to absorption,
denaturation and/or inaccurate reconstitution, so the advantages and disadvantages need to be
carefully considered.
Deﬁnition of target values
Target values should represent the “true” concentration of the analyte in EQA specimens and should
be both accurate and reproducible. Ideally target values should be obtained using an established
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In principle this is possible for homogeneous endocrine analytes for which full traceability of results is
achievable [8], i.e. Category I, II and III analytes such as the steroid hormones, as deﬁned in Interna-
tional Organization for Standardization (ISO) standard 17511 [9]. Many schemes for these analytes still
rely on consensus mean target values, but reference measurement targets are increasingly being
applied in schemes, including one for vitamin D [10], that are described as accuracy-based.
However, developing reference method (“accuracy-based”) targets poses signiﬁcant challenges for
heterogeneous analytes that occur in multiple molecular forms in body ﬂuids, i.e. Category IV and V
analytes [9] such as hCG, FSH and LH. It is also difﬁcult to deﬁne inaccuracy for heterogeneous analytes,
since clinical information that is equally valid may be provided by different assays measuring different
groups of isoforms. For the purposes of EQA, a trimmed consensus mean is usually pragmatically
adopted as the most appropriate target value. Trimmed consensus mean target values can be derived
from results reported by (a) all laboratories (all-laboratory mean), (b) all laboratories using groups of
methods (method-group mean) or (c) all laboratories using a single method (method mean). In the UK
NEQAS endocrinology schemes, the all-laboratory mean is generally adopted as the target value for
heterogeneous analytes, with the underlying assumption that its use may help to encourageTable 3
Data assessing of the validity of the all-laboratory mean as target value for a range of endocrine analytes in UK NEQAS.
Analyte Assessment of recovery Mean CV (%) of
method
means on repeat
distribution
Linearity of
all-laboratory
mean on
dilution
Overall between-
laboratory
agreement
(mean CV),
2012 [CV for 2003]
Analyte added/
comparator
Recovery (%)
Cortisol Pure chemical 102.0  1.4 0.6 (range 0–1.4) Yes 13% [11]
Oestradiol Pure chemical 89.1  7.0 1.8 (range 0–3.0) Yes 14% [26]
Progesterone Pure chemical 84.9  6.3 0.7 (range 0.3–1.2) Yes 9% [17]
Testosterone
[male matrix]
Pure chemical 96.5  3.0 0.7 (range 0.1–1.6) Yes 9% [11]
Testosterone
[female matrix]
Pure chemical 75.8  4.1 2.5 (range 0.6–4.5) No 21% [23]
Free thyroxine Not applicable Not applicable 0.4 (range 0–1.0) 11% [12]
Free triiodothyronine Not applicable Not applicable 1.2 (range 0.2–1.8) 9% [12]
Thyroid stimulating
hormone (TSH)
IS 81/56 102.5  4.6 0.2 (range 0–0.4) Yes 9% [12]
Anti-Müllerian
hormone (AMH)
No reference
preparation
– 1.9% (range 0.1–3.2) Yes 17% [27%a]
Follicle stimulating
hormone (FSH)
WHO 94/632 102.5  1.3 0.7% (range 0–1.2) Yes 15% [15%]
Human chorionic
gonadotrophin (hCG)
IS 07/634 96.8  1.4 0.8% (range 0.1–1.2) Yes 7% [15%]
Luteinising hormone (LH) IS 80/552 110.1  1.2 0.9% (range 0–1.7) Yes 17% [15%]
Prolactin IS 84/500 108.5  1.8 1.1% (range 0–1.7) Yes 17% [17%]
Adrenocorticotrophic
hormone (ACTH)
Synthetic
ACTH(1–39)
[Bachem,
Switzerland]
136.9  12.0 0.9% (range 0.2–2.5) Yes 10% [23%]
C-peptide IRR 84/510 85.8  2.4 1.9% (range 0.3–2.8)
Growth hormone IS 98/574 89.6  7.9 3.1% (range 0.0–9.4) Yes 13% [18%]
Insulin IRP 66/304 64.7  1.0 2.7% (range 0.4–4.6)
Insulin-like growth
factor I (IGF-I)
No reference
preparation
– 1.8% (range 0.1–4.9)
Parathyroid hormone Synthetic
hPTH(1–84)
[Peptide
Institute, Japan]
137.6  2.9 0.7% (range 0.1–2.3) Yes 25% [25%]
CV, Coefﬁcient of variation; IRP, International Reference Preparation; IRR, International Reference Reagent; IS, International
Standard.
a 2010 data.
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priate where there is a clearly deﬁned speciﬁcity difference between groups of methods [e.g. “intact”
and “total”method-groupmeans for hCGmethods, wheremethods are classiﬁed according towhether
or not they recognize the free beta-subunit of hCG [11]]. While method mean targets may be attractive
to participants, they tend to provide a misleadingly optimistic view of performance (e.g. masking the
effects of differences in calibration) and their use is generally undesirable.
The all-laboratory mean is easily calculated, broadly based and widely applicable. However its
accuracy (and also that of method-group means) cannot be assumed and must be regularly demon-
strated. This is best achieved by recovery experiments in which known amounts of the analyte [where
possible an International Standard (IS) or Reference Material for which commutability has been
experimentally demonstrated] are added to the same base pool and the observed means are then
compared with the calculated values, preferably by regression analysis. Some additional assurance of
the validity of the all-laboratory (or method-group) mean can be obtained by assessing its linearity on
distributing different concentrations of analyte in the same base pool and its stability (i.e. reproduc-
ibility) on issuing specimens of the same pool several times. Table 3 shows UK NEQAS data that support
the use of the all-laboratorymean as target values for a range of endocrine analytes for which observed
recoveries are within 10% of quantitative. The non-quantitative recoveries observed for ACTH, PTH,
insulin and C-peptide suggest that the all-laboratory mean may not be a valid target for these analytes.
The lack of universally adopted International Standards for ACTH and PTH is likely to contribute to the
over-recoveries observed. This is being addressed for PTH [3] and a similar initiative for ACTHwould be
desirable. Investigation of possible reasons for the low recoveries of insulin and C-peptide, which could
include loss of immunoreactivity during specimen preparation or non-commutability of the relevant
reference preparations, is also clearly desirable.Assessment of overall performance
This provides a measure of the “state of the art” for measurement of the analyte and is described in
terms of the all-laboratory mean and the scatter of results about that mean. Trimming of outlying
values using a robust statistical method such as that of Healy [12] provides a reliable estimate of the
mean. The mean of the CVs for all specimens issued over a reasonable time period (e.g. one year) can
then give a good indication of the state of the art. If sufﬁcient specimens are distributed, “precision
proﬁles” such as those shown in Fig. 2 allow conclusions to be drawn about performance over the
clinically relevant concentration range. Overall between-laboratory agreement for prolactin is clearlyFig. 2. Precision proﬁle showing the overall between-method agreement for all prolactin methods and within-method agreement
for two individual prolactin methods. [UK NEQAS data, 2012] [GCV, geometric coefﬁcient of variation] [Alternative version below].
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providers are well-placed to investigate some of the factors likely to contribute to poor between-
laboratory agreement, including errors in calibration, use of different reference preparations, differ-
ences in antibody speciﬁcity and differences in method design.
Trends in overall method performance with time can also give a helpful indication of whether
between-method agreement is improving. UK NEQAS data over the last ten years suggests that overall
between-laboratory agreement has not changed much for FSH, LH, prolactin and PTH, but that there
has been some improvement for hCG, ACTH and GH (see sixth column in Table 3). This is likely to reﬂect
better calibration and assay design, as well as increased use of automated methods, and may to some
extent also reﬂect method consolidation, with fewer methods now available from fewer suppliers.
Changes in the characteristics of EQA specimens issued (e.g. the range of analyte concentrations) may
also be relevant. It is interesting and encouraging to note that during this time period there have been
major standardisation initiatives for hCG [11] and GH [2], both supported by the International Feder-
ation of Clinical Chemistry and Laboratory Medicine (IFCC), which may have contributed to the
apparent improvement in overall agreement for these two analytes. Both initiatives involved intro-
duction of new International Standards and both focused the attention of the diagnostics industry on
the need for better between-method agreement for these analytes.
Assessment of individual method performance
EQA provides a unique tool for assessing the performance of individual methods under routine
conditions in a variety of laboratories [5], provided that for each method there are sufﬁcient users (at
least ﬁve and ideally at least ten) to enable reliable statistical analysis. Some aspects of method per-
formance that can be assessed for endocrine analytes are illustrated below.
Within-method between-laboratory agreement
Early conﬁrmation that the predicted greater robustness of two-site antibody excess immunoassays
was seen in practice [5] has been sustained. Within-method mean geometric coefﬁcients of variation
(GCVs) of <10% over the concentration ranges tested are consistently observed in the UK NEQAS
schemes for LH, FSH, PTH, ACTH and hCG [4]. GCVs appear to be somewhat less satisfactory (<15% over
the ranges tested) for GH and prolactin, although individual methods vary. As seen from Fig. 2, within-
method between-laboratory agreement for Method B is almost twice that observed for Method A over
much of the concentration range tested. Similar variation among methods is observed for most im-
munoassays. In general, greater precision is achievable with automated methods, as is clear in the Pilot
UK NEQAS for AMH, wheremean GCVs in excess of 50% are observed for amanual method as compared
with CVs less than 15% for a semi-automated method.
Method accuracy
Data from recovery experiments undertaken to validate the all-laboratory consensus mean target
values [see above] also enable assessment of the accuracy of method-groupmeans. These data can help
to elucidate reasons for differences in method bias, which may be due to incorrect standardisation, or
to correct standardisation of a non-speciﬁc assay. Fig. 3 shows the relationship between method BIAS
(i.e. mean cumulative bias from the target) and recovery of synthetic PTH(1–84) [Peptide Institute,
Japan] in the UK NEQAS for PTH. Relative recoveries of this material (which is not an established
reference preparation) range from 107% to 203%, suggesting that between-method agreement would
improvemarkedly if methods were calibrated in terms of the same standard.Working to achieve this is
among the aims of a recently established IFCC Working Group for PTH [3].
Method sensitivity
Analytical sensitivity can be assessed by issuing pools that are either analyte-free or contain
very low concentrations of the relevant analyte. Analyte-free sera may be obtained after
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triiodothyronine for TSH), although obtaining sufﬁcient volumes for distribution is likely to be
difﬁcult. Removal of analyte by chemical or immunoafﬁnity stripping is also possible, provided
alteration of the serum matrix and/or leaking of antibody from the immunoadsorbent can be
avoided. Fig. 4 shows results obtained when a pool of sera from males with low serum concen-
trations of FSH and LH was issued through the UK NEQAS for FSH. The results generally conﬁrm
reasonably good between-laboratory agreement at this very low concentration but it is clear that
between-laboratory variation for Methods C, D and G is greater than that for the other methods
shown. Good analytical sensitivity is particularly important in some clinical applications, e.g. for
LH and FSH when identifying hypogonadotrophic hypogonadism or for GH when monitoring
patients following treatment for acromegaly. As previously demonstrated on distributing speci-
mens known to give borderline results for GH and IGF-1, inadequate performance of methods
close to agreed decision limits for these analytes may seriously undermine the applicability of
international consensus criteria to local practice [7].0.0
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Method speciﬁcity can be investigated through EQA schemes by issuing appropriately consti-
tuted specimens containing physiological concentrations of potentially cross-reacting substances.
Such distributions provide an effective means both of elucidating what different methods measure
(e.g. recognition of the 20 kDa GH isoform or PTH(7–84) in methods for GH and PTH respectively)
and of reminding participants of the possible implications of such differences in clinical practice
[e.g. recognition of different analogues of insulin [13]], i.e. they can reinforce the importance of
knowing the speciﬁcity of the method used in order to minimise the risk of clinical misinterpre-
tation of results.
Fig. 5 shows results reported by participants using six major methods when a pool of pregnancy
serumwas issued through the UK NEQAS for LH. In accord with information supplied in the relevant kit
inserts, Methods E and G showmodest cross-reactionwith hCG, explaining the higher results observed,
while the other ﬁve methods shown do not. Such cross-reaction can help to identify unsuspected
pregnancy in a patient with amenorrhoea, provided clinical and laboratory staff interpreting the results
are aware of the characteristics of the method being used.Method robustness to clinically relevant interference
Interference from heterophilic and other antibody complexes
Other substances in clinical specimens may interfere and cause spuriously high or low results in
some assays [14,15]. Positive interference from heterophilic antibodies has been demonstrated through
EQA schemes for LH and FSH by issuing sera with and without added human anti-mouse antibodies
(HAMA) [5]. Difﬁculties in acquiring enough HAMA of appropriate provenance and high enough titre to
enable preparation of EQA pools with sufﬁcient concentrations unfortunately limits the frequency with
which such specimens can be prepared.
It is much easier to obtain serum containing macroprolactin, a high molecular weight complex of
prolactin with variable composition which also interferes to variable extents in different immunoas-
says [16,17]. Macroprolactin is considered to have minimal bioactivity in vivo. However apparent
hyperprolactinaemia due to unrecognised interference from macroprolactin can lead to misdiagnosis
and mistreatment. Fig. 6 shows the much greater variation in method mean results observed for a
specimen containing macroprolactin as compared with those for a macroprolactin-negative specimen
with a similar concentration of monomeric prolactin. Screening for macroprolactin is now routine
practice in many laboratories: monomeric prolactin can be determined in the serum supernatant after0.01
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NEQAS for Prolactin are requested to treat their prolactin EQA specimens exactly as they would patient
specimens and to undertake screening for macroprolactin for any specimens fulﬁlling their criteria for
screening patient specimens.
Medication
The inﬂuence of medication on analytemeasurements can also occasionally be probed through EQA
distributions. Pegvisomant is a drug that shows considerable homology with GH and is used for the
treatment of acromegaly at plasma concentrations approximately 1000-fold higher than those of GH.
On issuing pooled serum specimens containing GH with added Pegvisomant concentrations ranging
from 8000 to 494,000 mg/L, GH measurements in most assays were found to be artefactually low,
leading to the conclusion that the level of interference makes these assays unsuitable for studies of the
inﬂuence of Pegvisomant on GH neuroregulation [18].
Method robustness to high-dose hooking
In the presence of very high analyte concentrations, immunoassays may give falsely low results
if the capacity of the solid-phase or tracer antibody is exceeded [14]. Such “high-dose hook”
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centrations encountered in clinical specimens can range over several orders of magnitude (e.g.
from <5 U/L to >106 U/L for hCG). Although it is difﬁcult to obtain enough analyte to prepare a
sufﬁcient volume of an EQA specimen of concentrations high enough to “hook”, occasional dis-
tribution of such specimens provides a highly effective means of reminding participants of the
importance of having protocols in place to minimise the risk of reporting an erroneously low
result.
When a specimen containing approximately 870,000 U/L of puriﬁed hCG was issued through the
UK NEQAS for hCG, seven of 330 participating laboratories reported incorrect results. Four of these
were more than ﬁve hundred-fold less than expected (ranging from 42 to 1393 U/L) while two were
less than 3% of the expected value (10,000 and 27,800 U/L). A further two participants reported
“greater than” results that were too high (>1,500,000 U/L and >2,000,000 U/L), presumably
reﬂecting errors of dilution and/or transcription. As the methods were almost certainly performing
according to speciﬁcation, this EQA distribution highlighted the importance both of knowing the
characteristics of the method used and of having in place a protocol for introducing trigger points
that would identify the possibility of a “hooked” specimen and help to minimise the risk of
reporting an erroneously low result.
To reduce the possibility of adverse effects on patient results (e.g. due to accidental contami-
nation of a patient specimen), the high concentration EQA specimen was followed in sequential
number order by two EQA specimens prepared from the same base pool. This design conveniently
enables assessment of potential specimen “carry-over” as well as ‘hooking’. Most laboratories (91%)
reported essentially the same result for both these specimens, which was reassuring. However,
although specimen contamination (an error in itself) may have accounted for some of the 9% of
results which differed, the data suggested that at high analyte concentrations carry-over was oc-
casionally occurring, with two methods appearing to be particularly prone to this. The fact that
most users of these two methods avoided carry-over suggests that within different laboratories
there are variations in the parameters used for washing out automated systems between speci-
mens. Participants reporting erroneous results were advised to recheck their procedures and
consult the relevant manufacturers.
Audit of analytical practice
In the analytical phase, surveys of practice have focused the attention of participants on the
importance of screening for macroprolactin [16,19], helping to increase the proportion of respondents
undertaking screening from 81% in 2009 to 93% in 2012 [19]. This and similar earlier survey reports
have highlighted differences in laboratory policy including
 Whether a conﬁrmatory specimen is requested to exclude stress, medication, hypothyroidism,
pregnancy and other causes of raised prolactin prior to undertaking macroprolactin screening.
 The total prolactin concentrations that prompt macroprolactin screening (ranging from 260 to
1000 mU/L)
 The decision limits used to assess the presence of macroprolactin following polyethylene glycol
precipitation (percentage recoveries ranging from >14% to >70%).
 Whether estimated monomeric prolactin results are reported and accompanied by an appropriate
reference interval (only 24% of respondents in 2011).Assessment of individual laboratory performance
EQA schemes can generate informative and helpful data about both overall and method-related
performance, as described above. However, their main aim is to enable participating laboratories to
compare their performance with those of others and to provide independent assessment of
whether objective criteria for acceptable performance are being met. Some causes of unsatisfactory
performance in EQA are listed in Table 4, together with general guidance on points that the lab-
oratory should check.
Table 4
Unsatisfactory performance in EQA – general guidance on points that the laboratory should check. Where the cause remains
unresolved, the laboratory should discuss the problem with the EQA scheme provider.
Performance problem What should be checked
Assay bias  Method performance. Is the bias a feature of all labs using the method? Check with
manufacturer how method is calibrated.
 Consistently incorrect calibration of method by end user. Check the IQC data for
correctness and consistency of analyser set-up and calibration.
 Validity of EQA specimens for analyser platform. Could EQA specimen matrix or
preservatives interfere?
Assay imprecision  Unstable assay design and/or analyser platform. Check with manufacturer.
 Inconsistent calibration of method by end user. Check the IQC data for correctness
and consistency of analyser set-up and calibration.
 Analyser mis-sampling. Check IQC data
 Specimen mis-labelling in laboratory reception, or errors in linkage of results
to specimen in reporting.
 Check nature of EQA specimens included in performance time “window”.
Relative deviations of lab result from target may show high scatter due to, for example,
specimens with different matrix, or dose related bias.
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Rapid return of EQA reports (usually within a few days of the deadline for submission of re-
sults) is valued by participants and permits remedial action to be taken within a realistic time
scale. Personalised reports generally include histograms comparing individual laboratory results
with those of others for each specimen (Fig. 7). Most EQA schemes also provide each participating
laboratory with an indication of its bias (mean deviation of results from the target) and the
variability or scatter of that bias, using statistical procedures that depend on scheme design and
have been described elsewhere [20]. Many of these involve averaging data over several specimens
to provide cumulative estimates. In the UK NEQAS Endocrinology schemes the cumulative mean
bias and the geometric coefﬁcient of variation of that bias are calculated over a six-month win-
dow, providing ﬁgures respectively termed BIAS (i.e. the B score) and VAR (i.e. the C score,
reﬂecting consistency of BIAS) [5]. In most of these schemes specimens containing puriﬁed an-
alyte (e.g. International Standards) are excluded from all calculations of the cumulative statistics
as they are likely to be more homogeneous than the circulating analyte present in clinical
specimens.
Interpretation of performance statistics requires care since they may be affected by differences
associated with specimen type (e.g. differences in recognition of puriﬁed and endogenous analyte) or
concentration-dependent changes in bias and imprecision. Such effects may also contribute to
apparent differences in perceived performance occasionally observed by laboratories participating in
more than one EQA scheme for the same analyte.Fig. 7. Histogram showing typical results for a single specimen in the UK NEQAS for Prolactin. Results reported vary from <400 to
>1000 mU/L.
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that illustrated in Fig. 8. The ﬁrst column provides information about the pools issued, i.e. whether a
normal serum base pool or a base pool containing added endogenous or exogenous prolactin. Pools in
parentheses have been excluded from calculations of the cumulative statistics. The next six columns
summarise EQA data for six consecutive months. Within each column, the target value appears in bold
in the centre, with the participant’s results on the left and the % deviation from the target (i.e. bias) on
the right.
The results presented in Fig. 8 have been modiﬁed to illustrate the variety of information that
can be obtained from EQA data. Dose-dependent bias is observed in Distribution 396, with devi-
ation from the target increasing from 20.2% for the lowest concentration pool to þ74.7% for that of
the highest.
In Distributions 397 and 401, two specimens have been excluded from calculations of the cu-
mulative statistics (as indicated by the parentheses) because they contain puriﬁed (exogenous)
prolactin and are part of a recovery experiment. The specimens that have been excluded in Dis-
tributions 398 and 399 are endogenous but contain macroprolactin. Comparison of the results
reported for these specimens (933 mU/L and 723 mU/L respectively) with the consensus means
(427 mU/L and 424 mU/L) conﬁrms that the method being used is vulnerable to interference from
macroprolactin. The extent of recognition of the macroprolactin present in each specimen is
different, with deviations from the target of þ118.6% and þ70.5% respectively, demonstrating that
the extent of interference varies even within-method according to the nature of the particular
macroprolactin. As recognition of macroprolactin varies between-method, it is clearly not appro-
priate to include these specimens in any calculations of the cumulative statistics. RepeatedFig. 8. Analysis of Bias sheet from monthly report issued to participants in the UK NEQAS for Prolactin. Individual laboratory results
are listed across the page for six monthly distributions and by pool down the page. [See text for further explanation].
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dividual laboratory results, although no such pools were issued during the six month period
illustrated in Fig. 8.Recording of participant errors
Several errors occasionally made by participants are also illustrated in Fig. 8. In Distribution 399, an
analyser mis-sample has led to an erroneously low result of <60 mU/L being reported when the
consensus mean was 835 mU/L. In Distribution 400, specimens have been booked-in in reverse order
so that only the result of 872 mU/L is correct. As a result of a transcription error 1760 mU/L rather than
176 mU/L has been reported in Distribution 401. Other common causes of error include failure to
inform the EQA centre of a change of method, failure to modify practice in response to new technical
advice provided by the manufacturer and inadvertent re-setting of reporting units in an analyser
following a service or software update. Erroneous results for which no cause can be identiﬁed also
occur. Some of these errors are EQA-speciﬁc. Most clinical results are automatically uploaded from the
analyser to the laboratory computer but as yet this is not usually feasible for EQA specimens, so
transcription errors made when submitting results are unlikely to occur in clinical practice. An
important exception to this is pregnancy testing using qualitative point of care testing (POCT) devices,
since such results are frequently not uploaded to laboratory computers. Errors made when reporting
EQA results from POCT units are therefore likely to reﬂect the number of errors made for clinical
specimens, which may have particularly serious implications for patient care. Provided participants
handle EQA specimens as they would clinical specimens, the proportion of many of the types of errors
observed for EQA specimens is likely to be similar to that observed for clinical specimens. Conﬁrmed
analytical errors (i.e. specimens notiﬁed as having incorrect results expressed as percentages of the
total specimens analysed) in the UK NEQAS schemes for gonadotrophins, prolactin, growth hormone,
PTH and ACTH have for some years been 0.2% but are higher (0.5%) for AMH, where most results are
obtaining using manual or semi-automated rather than fully automated methods. Since not all errors
are notiﬁed to EQA centres, these ﬁgures are likely to under-estimate the errors made for clinical
specimens, probably by at least a factor of two. In order to ensure that evaluation of method perfor-
mance is not compromised, on receipt of a written explanation, notiﬁed errors are recorded and
corrected.Scoring of performance and external review
Participation in EQA clearly has regulatory elements even in schemes where the ethos is
educational and collaborative rather than regulatory. Limits of acceptable performance are gener-
ally established nationally. In the United Kingdom limits are proposed by EQA providers and agreed
by their professional advisory groups before being submitted to the relevant National Quality
Assurance Advisory Panel (NQAAP) for approval. The statistical parameters used for quantitative
analyses are essentially measures of BIAS (or the equivalent “B” score) and VAR (or the equivalent
“C” score), as described above. Acceptable performance limits, which are regularly reviewed, are
generally BIAS within 15, 20 or 25% of the target and VAR 15, <20 or <25%, depending on the
analyte.
Participants are identiﬁed as having unsatisfactory performance if their BIAS and/or VAR scores
exceed the limits for three consecutive distributions. EQA providers are allowed some ﬂexibility in
applying these limits, since for these heterogeneous endocrine analytes, performance outside the
limits may reﬂect method-related differences rather than poor laboratory performance. Participants
with performance issues which cannot be resolved through dialogue with the EQA provider are
referred to the NQAAP, which can take action including reporting the laboratory to accreditation bodies
and hospital management. Perhaps due to the collaborative ethos between participants and EQA
providers that is promoted in the UK, most problems are addressed satisfactorily without NQAAP
intervention. Where problems are method-related, EQA providers are encouraged to engage in
constructive dialogue with manufacturers to stimulate and aid resolution.
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EQA providers have a readily available organisational infrastructure that enables ready communi-
cation with their participants and analysis of data provided by them. EQA accordingly provides a
powerful tool with which to conduct audits of wider aspects of laboratory performance. The results of a
few such audits are brieﬂy described here together with conclusions of a published audit on test
requesting.
Assessment of pre-analytical quality
Appropriateness of test requesting
Selecting the most appropriate endocrine tests for a particular patient is perhaps more straight-
forward in endocrinology than in some other medical specialties. In patients with signs and symptoms
suggestive of disease associated with particular endocrine systems, hormone measurements provide
relatively sensitive and speciﬁc markers of functional disturbance, and optimum test protocols are well
described (e.g. for the thyroid and reproductive hormones listed in Table 3). Excellent clinical guide-
lines which specify which tests should be done arewidely available (e.g. those of the American [21] and
British [22] Thyroid Associations, the Endocrine Society [23], and the Royal College of Obstetrics and
Gynaecology [24]). The close links between endocrinologists and their laboratory colleagues usually
mean that these guidelines are translated into local protocols which can be made readily available to
non-specialist requestors.
Although encouraging appropriate test requesting has been identiﬁed as one of the top ten quality
indicators for laboratory medicine [25], there are relatively few published audits of requesting patterns
for endocrine tests. Results of a controlled study performed in New Zealand conﬁrm that audit, coupled
with active promotion of guideline recommendations, can be effective [26]. Thyroid function test
request patterns were compared in two large groups of general practitioners, one of which (the
“intervention group”) received information about guideline recommendations, individual laboratory
test-use feedback and professional development opportunities. Requests for free thyroxine and free
triiodothyronine decreased by 44.1% and 36.0% respectively in the intervention group, while the
proportion of thyroid function tests where TSH was the sole test ordered increased from 43.2% before
the intervention to 65.2% afterwards. Reporting such audit activity can helpfully encourage similar
activity by others. In practice, while such initiatives may be national, they are more often local or
regional. While highly desirable in terms of total quality management, audit and improvement of test
requesting patterns have hitherto not generally been considered part of either internal quality control
activities or external quality assessment provision, mainly because of the difﬁculty of addressing these
[27], although some EQA schemes actively encourage their participants to implement guideline rec-
ommendations about test requesting, e.g. through educational meetings and commentaries.
Clinical guidelines are helpful in encouraging appropriate use of existing tests, but are usually not
available for newly developed tests. The introduction of a new test such as anti-Müllerian hormone
(AMH) into routine clinical practice provides a unique opportunity to ensure appropriate requesting
patterns from the beginning by effective education of users, preferably electronically at the time the
request is made [28].
Patient preparation and time of sampling
Such educational initiatives, which should include careful training of phlebotomists, can also help to
ensure that specimens for endocrine testing are taken under appropriate conditions. Fasting specimens
are required for meaningful results for some endocrine tests (e.g. insulin) while pre-test withdrawal of
medication is essential for others (e.g. beta-blockers prior tomeasurement of gut hormones). Specimen
timing is also important for endocrine measurements which are inﬂuenced by the time of day (e.g.
cortisol), menstrual cycle (e.g. LH, FSH, oestradiol and progesterone) or season (e.g. vitamin D). In-
formation about specimen requirements is usually conveniently provided in electronic form in labo-
ratory handbooks posted on hospital intranets and may also be available on websites sponsored by
professional organisations (e.g. “Assay Finder” from the UK Association for Clinical Biochemistry and
Laboratory Medicine [29]).
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Some endocrine tests (e.g. ACTH, calcitonin, gastrin and PTH) are unstable and require rapid
separation from the blood clot after sampling. Whether serum or plasma is required is often
method-dependent so recommendations made by manufacturers in the package inserts should
always be followed. Delay in transferring specimens to the laboratory and storage conditions after
arrival can also contribute to pre-analytical error, as has been extensively discussed elsewhere [27].
For some analytes there is relatively little published information about specimen stability before
and after separation from the clot or during storage. More systematic reviews of available evidence
such as one recently undertaken for PTH [30] would be desirable and would help to identify gaps in
existing knowledge.
Audit of pre-analytical practice
Surveys undertaken through EQA schemes can efﬁciently identify differences in laboratory advice
about specimen handling and provide a means of re-auditing following educational intervention. For
example, a survey of participants in the UK NEQAS for PTH in 2003 showed that there was no
consensus in recommended specimen type, even among users of the same method. Of the 124 re-
spondents to the Survey, 74% advised that specimens could be delivered to the laboratory at room
temperature while 21% required transport on ice. Since then there has been increased awareness of the
greater stability of PTH in EDTA plasma as compared to serum, which, together with a recent
recommendation from the IFCC Working Group for PTH that EDTA plasma is the preferred matrix [30],
is likely to change practice. EQA schemes are well-placed to assess progress with this through further
surveys.
Post analytical assessment
Surveys of current laboratory practice
As illustrated above, EQA also provides a powerful means of collecting and disseminating current
information about laboratory practice through circulation of questionnaires to participants and sub-
sequent preparation of a synopsis of the collated results. These reports can be of considerable
educational beneﬁt, encouraging laboratories that are out-of-consensus to re-examine and modify
their procedures.
Surveys of reference interval data have highlighted differences in the ranges quoted even
among users of the same analytical method. For example a survey conducted in 2007 found that, in
the female follicular phase, FSH upper limits quoted by users of a single method varied by more
than four-fold, from 5 to 23 U/L. Survey results for most endocrine analytes demonstrate differ-
ences in quoted upper limits for different methods which generally do not reﬂect differences in
method bias. Survey data also conﬁrm that the sources of reference intervals quoted in different
laboratories vary considerably and may include information from kit inserts, recent in-house data,
historical in-house data and/or literature reports. This is likely to contribute to the differences
observed but it is salutary to note that even when laboratories state that they are using only in-
formation provided by the manufacturer, the numerical values often differ. EQA schemes can
effectively document such variation but can only encourage participants to bring their reference
intervals into consensus. However recent initiatives such as those of Pathology Harmony [31] and
the National Laboratory Medicine Catalogue [32] in the UK may provide the additional impetus
required to achieve this.
Interpretation of results
Some EQA providers also supplement assessment of analytical performance with assessment of
participants’ ability to interpret their EQA results. The clinical background against which results are
interpreted must be carefully designed and the information provided similar to the rather minimal
information usually available to laboratory staff on laboratory request forms. Ideally, interpretation
should be requested as free text so as not to inﬂuence the responses. Meaningful exercises are chal-
lenging to design and time-consuming to analyse but they can have considerable educational value. As
participants are commenting on their own results, they can also illustrate very effectively the potential
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mistake for an EQA specimen included in the exercise.
In an interpretative exercise that accompanied distribution of a pool of pregnancy serum issued in
the UK NEQAS for LH (Fig. 5), a specimenwas accompanied by the following clinical details: “Infertility.
Two months amenorrhoea.” Participants were asked what comment they would make about their
result in the light of these details. Interpretations provided included comments correctly suggesting
the result could be consistent with pregnancy and/or that hCG should be measured (88% of re-
spondents), use of oral contraception (27%), and/or pituitary or hypothalamic disease (18%). [Re-
spondents often made more than one comment so percentages do not add up to 100%.] Further tests
suggested included oestradiol, thyroid function tests, cortisol, testosterone, and progesterone. The
report subsequently circulated to all participants included the suggestion that an adequate comment
would be “Assuming patient not on oral contraceptive medication, results could be consistent with
pregnancy” together with a recommendation that the laboratory should contact the requesting
clinician to offer to check hCG on the specimen.
Similar exercises have been conducted in which relevant EQA specimens have been accompa-
nied by clinical details relating to the interpretation of gonadotrophin and prolactin results in
polycystic ovarian syndrome, oligomenorrhoea and premature ovarian failure, growth hormone
results in patients with treated acromegaly and children being investigated for short stature, PTH in
patients with hypercalcaemia, ACTH in patients following administration of synthetic ACTH or
dexamethasone [19]. While these exercises have some limitations they highlight variability in both
analytical and interpretative aspects of endocrine service provision and can help to identify pri-
orities for improved consensus. These conclusions are strengthened considerably if clinicians who
use the tests review and comment on the draft reports, as has been the case for the exercises
described above.
Other aspects of EQA provision
Some EQA providers can provide comparative “method-related” reports which are particularly
helpful to participants considering a change of method. “Network reports” summarising perfor-
mance for multiple analysers at the same or different sites, are also helpful in monitoring service
quality and consistency. Previously issued specimens are also usually available for comparison
studies. Most EQA schemes encourage participation of and dialogue with diagnostics manufac-
turers, both for established methods and for methods in development. For the latter, participation
at an early stage can identify issues that need to be addressed before a method is launched. Brief
summaries of recent relevant literature are provided by some EQA schemes as an additional service
to participants.
Summary
Producing high quality endocrine results to support high class patient care requires care and
attention to detail from many professionals. Close collaboration between clinical and laboratory
staff to develop protocols for appropriate test requesting is essential, with such information made
readily available to all laboratory users. Analytically, clinical laboratories should ensure that robust
IQC procedures are in place and that appropriate remedial action is taken as soon as any divergence
from expected performance is observed. IQC and EQA specimens should resemble patient speci-
mens and be of physiologically relevant concentrations, including those close to clinical decision
and lower reporting limits. EQA providers have a responsibility to provide relevant information to
their participants that includes for each analyte an objective assessment of individual laboratory
performance, comparative information about the performance of methods in the ﬁeld, and an
overall view of agreement across all methods. Such information can be supplemented with reports
on interpretative exercises and surveys of practice that enable participants to compare their own
practice with that of others. Where feasible, EQA providers should also contribute to national and
international standardisation and harmonisation initiatives to improve between-method compa-
rability of results for these important analytes and thereby facilitate the implementation of clinical
guidelines.
Practice points
 Providers of EQA of hormone determinations should ensure that the data they provide is as
reliable as practically possible. This requires as a minimum that specimens issued are
appropriate for the methods surveyed, that target values used to assess laboratory and
method performance are accurate, and that participants receive timely and comprehensive
reports relating to their results.
 Participants in EQA schemes should ensure that when EQA specimens are processed in their
laboratory the results as far as possible truly represent their performance for routine clinical
specimens. Where poor performance is found possible causes – including errors occurring
before, during and after the analytical stages – should be investigated immediately.
 Manufacturers of diagnostic systems should use EQA data to monitor performance of their
systems in the ﬁeld. They should ensure that their assays are calibrated as directly as possible
to the best available International Standard.
 Clinicians should ascertain from the laboratories they use the laboratory’s accreditation
status and where necessary the EQA performance for the hormone tests of interest. The
source of the laboratory’s reference ranges and any interpretative guidelines should also be
established where required.
 Laboratory accreditation agencies assessing a laboratory’s competence to practice should
include EQA performance data in their assessment, always bearing in mind the validity of the
EQA scheme data.
Research agenda
 Continued critical evaluation of EQA data to ensure its validity as an audit tool, e.g. specimen
suitability for existing and newly developed analytical platforms, stability and accuracy of
target values over time.
 Continued use of EQA for occasional testing of method robustness, e.g. method vulnerability
to interferences from endogenous antibodies, high-dose hook effects.
 Continued educational activities of EQA schemes to maintain awareness of sources of error
and to promote good laboratory practice.
 Development of a mechanism for improved dialogue among providers of EQA for endocrine
tests with the aim of elucidating reasons for apparent differences in performance that are
perceived in different schemes.
 Continued active participation in national and international standardisation initiatives to
improve the comparability of endocrine test results.
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